2014 Fiat 500l Easy New Turbo 1.4l Hatchback Premium Repairable Rebuilder Ez Fix on 2040-cars

Auto blog

Stellantis launching at least 25 EVs for America by 2030

Stellantis has announced a wide-ranging plan for the company through 2030 covering everything from product to financials. The product plans are what really caught our attention, particularly for the surprise reveal of the first electric Jeep, as well as new teasers of the electric Ram 1500. But the company also provided more broad details on what we'll be seeing in the future including both electric cars and hydrogen fuel cell vehicles. All of the plans are in service of the Stellantis goal of reaching net zero carbon emissions by 2038. On that way, it plans for all European vehicle sales and half of all American sales to be electric by 2030. It will launch 75 new electric vehicles by that year, and at least 25 of them will be coming to the U.S. The first of those electric cars will be the aforementioned Jeep in 2023, but many Stellantis models will follow close behind. The electric Ram ProMaster will launch in 2023 as well. In 2024, we'll see the electric Ram (and its plug-in hybrid counterpart), two more Jeeps (an off-road model and a family-oriented model) and the Dodge electric muscle car. We'll get a preview of the Dodge with a concept this year. Then in 2025, Chrysler will launch its electric car, likely based on the Airflow concept. Stellantis has previously announced Chrysler will be fully electric by 2028, and it further announced that Alfa Romeo and Maserati will be fully electric by 2030. Stellantis is also working on hydrogen fuel cell vehicles, mainly for commercial use. For the U.S., it plans on offering a large, ProMaster-size hydrogen van in 2025. That year or a little later, it also has plans for a hydrogen heavy-duty pickup truck, presumably Ram 2500 and 3500. Stellantis CEO Carlos Tavares noted that among the benefits of hydrogen for large and commercial vehicles is being able to avoid compromising payload capacity, since hydrogen powertrains are lighter than giant batteries. Hydrogen filling times are quick relative to charging, too. The company will continue working on and offering advanced driver aids. This year it will offer hands-free cruise control like GM's Super Cruise and Ford's BlueCruise. In 2024, the company intends to introduce a system that is hands-free and won't require the driver to be watching it the entire time. The technology is being developed alongside BMW. These are, of course, broad plans, and they could change as time goes on. Expect more details as we get closer to individual product releases.

Apple picks up former FCA quality boss Doug Betts

Apple made a significant personnel move that further signals its entry into the automotive world, hiring former Fiat Chrysler executive Doug Betts for an unspecified role. The information was obtained by The Wall Street Journal, which cites Betts' LinkedIn page. His career included stints at Toyota and Nissan before joining Chrysler Group (now FCA US LLC) in 2007, although his time there didn't end well. He left FCA, where he served as the automaker's head of quality, after the company's dismal showing in Consumer Reports' 2014 Annual Auto Reliability Survey. According to Betts' LinkedIn profile, which has since been pulled down, his job title reads "Operations – Apple Inc" in the San Francisco Bay area. Apple, meanwhile, was unwilling to divulge anything to the WSJ, although there's plenty to infer based on the hire. Betts wasn't the only big auto-related hire. According to the WSJ, Cupertino also lured an unnamed but "leading" autonomous vehicle researcher from Europe, who will be part of a team being setup to study driverless systems. Related Video:

Fiat Chrysler says it did not know about Marchionne's illness

ZURICH/MILAN — Fiat Chrysler said it knew nothing about the medical condition of Sergio Marchionne after a Swiss hospital said on Thursday it had been treating the deceased chief executive for more than a year. "Due to medical privacy, the company had no knowledge of the facts relating to Mr. Marchionne's health," a Fiat Chrysler spokesman said. Questions have been raised about how long Marchionne, who died on Wednesday, was ill and how much the company knew before it made the situation public. Marchionne rescued Fiat and Chrysler from bankruptcy after taking the wheel of the Italian carmaker in 2004 and he multiplied Fiat's value 11 times through 14 years of canny dealmaking. He was due to step down at FCA in April next year. "The company was made aware that Mr. Marchionne had undergone shoulder surgery and released a statement about this," the spokesperson said. "On Friday, July 20, the company was made aware with no detail by Mr. Marchionne's family of the serious deterioration in Mr. Marchionne's condition and that as a result he would be unable to return to work. The company promptly took and announced the appropriate action the following day." Asked whether the scope of the statement included the board and the chairman, the company declined to comment. In emailed comments, Marchionne's family confirmed the companies had not been aware of his health conditions. "At the end of last week FCA was made aware Sergio Marchionne would no longer be able to return to work without mentioning any further details," the family said. The announcement of the death of Marchionne, 66, one of the auto industry's most tenacious and respected CEOs, drew tributes from rivals and tears from his closest colleagues on Wednesday. University Hospital Zurich said earlier on Thursday Marchionne had been treated for a serious illness for more than a year before his death. Marchionne had fallen gravely ill after what the company had described as shoulder surgery at a Zurich hospital. He was replaced as chief executive last weekend after Fiat Chrysler (FCA) said his condition had worsened. "Mr. Sergio Marchionne was a patient at USZ. Due to serious illness, he had been the recipient of recurring treatment for more than a year," the hospital said in a statement. "Although all the options offered by cutting-edge medicine were utilized, Mr.